Exciting Developments from Adagene's Clinical Studies
Adagene Inc. (Nasdaq: ADAG), renowned for its innovative approaches in discovering and developing antibody therapies, is poised to unveil new clinical data concerning its lead program, ADG126, designed for treating advanced forms of colorectal cancer. The presentation will happen at a prestigious conference which garners the attention of leading medical professionals and researchers in the field.
Overview of the ADG126 Clinical Study
The ongoing Phase 1b/2 trial is an open-label and multicenter study focusing on the efficacy of ADG126 when combined with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab). This trial specifically investigates the impact of this combination therapy on patients with microsatellite stable (MSS) colorectal cancer, a cohort that has traditionally faced limited treatment options.
Notable findings from previous segments of the study highlighted promising results, particularly at a dosage of 10 mg/kg. The forthcoming presentation looks to expand on this with fresh data, including initial outcomes observed from a higher 20 mg/kg loading dose followed by a continuation with the standard 10 mg/kg regimen.
Details of the Upcoming ASCO Gastrointestinal Symposium Presentation
The upcoming presentation titled "Update of phase 1b/2 study of muzastotug (ADG126, an anti-CTLA-4 SAFEbody) in combination with pembrolizumab in advanced/metastatic MSS CRC" will take place at the highly anticipated ASCO Gastrointestinal Cancers Symposium. This event will draw significant attention from oncologists and researchers alike.
The details for the poster session are as follows:
- Date: January 25
- Time: 7:00 AM - 7:55 AM Pacific Time
- Venue: Moscone West, San Francisco
- Abstract Number: 193
- Poster Board: H5
After the presentation, attendees can access the poster on the Publications page of Adagene's official website.
Interactive Discussion on Advanced Treatments
On the same day, the company will also host a virtual Key Opinion Leader (KOL) event featuring experts in the oncology field. Esteemed speakers including Dr. Aurélien Marabelle from Université Paris-Saclay, alongside Dr. Daneng Li and Dr. Marwan Fakih from the City of Hope, will engage in discussions surrounding the critical needs and innovative strategies for treating advanced/metastatic MSS colorectal cancer.
This session aims to shed light on the role of CTLA-4 targeting in achieving lasting therapeutic responses, particularly in challenging tumor environments. It is an excellent opportunity for stakeholders to hear from researchers who are at the forefront of oncological innovation.
About Adagene's Innovations in Cancer Treatment
Adagene is a clinical-stage biotechnology company relentlessly pursuing breakthroughs in cancer immunotherapy. Leveraging its proprietary Dynamic Precision Library (DPL) platform, Adagene crafts highly specialized antibodies, addressed towards the unique needs of cancer patients worldwide.
One of the flagship innovations, SAFEbody technology, is noteworthy for its precision masking capability, enhancing the therapeutic window of antibody drugs while mitigating undesirable side effects. This meticulous design allows ADG126 to focus on targeting tumors effectively, therefore shielding healthy tissues during treatment, a significant advancement that could change standard practices in cancer therapy.
ADG126, specifically, is targeted at the CTLA-4 receptor present on Tregs within the tumor microenvironment. Designed to be administered in combination with anti-PD-1 therapies, this novel approach could enable more efficient and sustainable treatment options for MSS colorectal cancer patients.
For continual updates and in-depth information on Adagene's research and clinical endeavors, interested parties are encouraged to visit the official investor website.
Frequently Asked Questions
What is the significance of ADG126 in cancer therapy?
ADG126 is designed to target CTLA-4 receptors specifically in the tumor microenvironment, making it a promising candidate for enhancing the efficacy of existing cancer treatments.
When and where will Adagene present its latest data?
Adagene will present updated data at the ASCO Gastrointestinal Cancers Symposium on January 25, at Moscone West in San Francisco.
Who are the key opinion leaders participating in the virtual event?
Notable speakers include Dr. Aurélien Marabelle, Dr. Daneng Li, and Dr. Marwan Fakih, who will discuss the current treatment landscape for colorectal cancer.
What combination therapy is ADG126 tested with?
ADG126 is being tested in combination with KEYTRUDA (pembrolizumab), a well-known anti-PD-1 therapy.
How does SAFEbody technology improve cancer treatments?
SAFEbody technology improves safety and tolerability by masking the drug's active components until they reach the tumor, thereby reducing side effects on healthy cells.
